Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-05-20

Clinical Trial Update: Safety Study of Replagal® Therapy in Children With Fabry Disease [Phase 2]

View source ↗

Summary

Phase 2 safety study of Replagal therapy in children with Fabry disease has completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Replagal (agalsidase alfa)

Snippet

Sponsor: Shire | Conditions: Fabry Disease | Phase 2 | Status: COMPLETED | Results posted: 2014-05-20